The protein truncation test (PTT) is currently the fastest method in general use for detecting previously unidentified mutations in tumor suppressor genes. Greater than three kilobases of coding sequence can be screened by one PCR reaction, one coupled in vitro transcription/translation reaction, and one lane on an SDS-PAGE gel. The 16 kb of BRCA1/2 coding sequence can be screened with nine overlapping segments. Since 90% of BRCA1/2 mutations result in a truncated protein product, the theoretical false negative rate for a BRCA1/2 PTT screen should be 10%. In practice the false negative rate is much higher, especially when cDNA is used as template. However, the actual false negative rate for a given screen will depend on the details of how the test is performed. Design of the overlapping segments, gel parameters, and nonsense mediated mRNA decay can all influence the effectiveness of the screen. BRCA1/2 screening by PTT can be optimised by considering these variables. Furthermore, nonsense-mediated mRNA decay can be inhibited by blocking protein synthesis with cycloheximide.
Introduction
The protein truncation test (PTT), also referred to as the in vitro synthesised protein assay (IVSP), was first described by Roest et al 1 and Powell et al 2 as a means of detecting mutations in the dystrophin gene and the APC gene, respectively. Using PTT, one can identify the subset of genetic mutations which result in a truncated protein product by synthesising the protein encoded by a test sequence in vitro and determining its size. Although PTT is an indirect approach to identifying alterations in DNA and is unable to detect missense mutations, it has become a popular screening method because it is such an efficient means of screening coding sequence. Alternate approaches such as SSCP and direct sequencing require much more effort per megabase screened than PTT, and generate excess data that are irrelevant to mutation detection. For example, sequencing will determine the nucleotide sequence of a gene (virtually all of which will be wild type) in addition to detecting alterations that predispose to disease. Similarly, SSCP detects benign polymorphisms as well as disease-causing mutations. PTT, on the other hand, only detects alterations in a coding sequence that lead to a truncated protein product. Fortunately, many genetic diseases are caused by inheritance of loss of function mutations, and premature truncation of the protein product is a common mechanism leading to loss of function. Thus a protein truncation assay can efficiently detect mutations predisposing to disease.
Protein truncating mutations are commonly found in genes predisposing to cancer. For example, 95% of the APC gene mutations associated with familial adenomatous polyposis 3 and 71% of the mutations in the mismatch repair genes predisposing to hereditary nonpolyposis colorectal cancer 4 are translation terminating mutations. The breast cancer susceptibility genes BRCA1 and BRCA2 follow the same pattern. Eightysix percent of BRCA1 mutations detected by sequencing and SSCP generate a truncated protein, 5 as do 20 of the first 21 (95%) reported BRCA2 mutations. 6, 7, 8 More recently detected mutations described in the BIC online data base confirm this trend. 9 These truncating mutations are dispersed throughout the 48 exons containing the 16 kb of BRCA1/2 coding sequence, implying that a screen of the entire coding sequence is appropriate. In certain human subpopulations, such as the Ashkenazim, founder effects will allow for efficient screening of specific mutations. 10 However, in most clinical settings the heterogeneity of the patient population and the large number of still unidentified BRCA1/2 mutations will result in an unacceptably high false negative rate for allele specific testing. The recently described DNA chip-based assay promises to offer high throughput detection of novel BRCA1/2 mutations, 11 although this technology is not yet available for routine diagnostics.
PTT has been used by at least three groups to screen the entire BRCA1 coding sequence. [12] [13] [14] In each case, the general strategy is the same: cDNA is used as PCR template for the 21 smaller exons containing 40% of the coding sequence, while the 3427 basepairs (60% of the coding sequence) of exon 11 are amplified from genomic DNA. BRCA1 is PCR-amplified in five or six overlapping segments of convenient size, and the entire gene is screened for truncating mutations by analysing the five or six PCR products by in vitro transcription/ translation and SDS-PAGE. In the three publications cited, 138 patients were screened by PTT for BRCA1 exon 11 mutations using gDNA as template, and 10 novel mutations were detected; 95 patients were screened by PTT for mutations in exons 2-10 and 12-24 using cDNA as template, yet not a single mutation that could be verified by an alteration in the DNA sequence was identified. Thus the ability of PTT to detect BRCA1 mutations appears to be below its theoretical expectations, especially when cDNA is used as starting material.
The disappointing detection frequency for PTT is most likely due to a number of technical factors that must be addressed. Firstly, the overlap between segments must take into account the inability of tris/ glycine buffered SDS-PAGE to resolve proteins smaller than 12 kilodaltons. Secondly, means must be found to minimize and cope with the background signals caused by PCR artifacts that can arise when cDNA is used as template. Thirdly, the problem of nonsense mediated mRNA instability must be solved.
Materials and Methods

Template Preparation
Genomic DNA was isolated by the salting-out method. 15 For cDNA, PBLs from 20 ml of fresh heparin-treated blood purified by Ficoll hypac, or 10 7 cells grown in tissue culture are used to make total RNA isolated with the Triazol reagent (Gibco, Basel, Switzerland). The RNA pellet is used directly to make cDNA by random priming MoMuLV RT. Final volume of the RT rxn is 50 µ1. The cDNA is heat treated for 5 min at 95°C and is used directly for PCR.
PCR
Hot start is done for all PCR reactions. All PCR reactions using genomic DNA as template are performed in a final volume of 20 µ1, 100 ng of template, with primer concentration at 200 nM. Amplification is achieved by 50 cycles of PCR with 2 mM MgCl 2 and 1 U thermostable polymerase consisting of a mixture of 40 parts Taq to 1 part Pwo, a thermostable polymerase with proofreading activity (GIBCO BRL, Basel). All cycling is done at 94°C for 30 s, 55°C for 30 s, 68°C for 2 min, except for segment 5 which works best with a hybridisation temperature of 50°C. Segments requiring cDNA template are amplified in two steps using 1 µl of cDNA. In the first step, external primers at 200 nM in a final volume of 10 µl are used for 20 cycles of amplification. Internal primers are then added to the 10 µl of PCR products to a final concentration of 400 nM in 30 µl and 30 cycles are performed with the same temperature/time profile and enzyme concentration as above. There are three exceptions to these primer concentrations -external segment 4 primers are at 100 nM, and internal segment 4 and internal segment 8 primers are at 250 nM final concentration.
PTT
The PCR products are transcribed into BRCA1/2 mRNA and translated into protein simultaneously using a minimum amount of PTT reagent similar to that provided in the TNT coupled transcription/translation kit from Promega (Madison, WI, USA), but having one-fourth the concentration of labelled methionine and a homemade buffer. The PTT reagent is made up in bulk and frozen in aliquots once at -70°C. 1.2 ml of PTT reagent is made as follows: 1 ml rabbit reticulocyte lysate and 40 µl 1 mM amino acids minus methionine from Promega (Madison, WI, USA), 40 µl high concentration (90 units/µl) T7 polymerase, 40 µl translational grade S35-methionine, and 20 µl RNASE inhibitor (90 U/µl) from Amersham (Buckinghamshire, UK). To these five components is added 80 µl of a homemade buffer that consists of 10 mM rNTPs and 25 mM MgCl 2 .
A complete PTT for BRCA1 and BRCA2 A Garvin 227 2 µl of PCR product (at 2 mM MgCl 2 ) are added to 3 µl of PTT reagent and incubated at 30°C for 1 h. After the reaction is complete, 10 µl of loading buffer containing SDS and BME are added to each sample, the samples are heated to 95°C for 2 min, and 5 µl of each is subjected to tris/glycine discontinuous SDS-PAGE on a 5-18% gradient gel at 35 ampere constant current for 120 minutes. When the bromophenol blue dye has reached the bottom of the gel, the gel is fixed in methanol/acetic acid for 30 min, dried and used to expose Kodak Biomax film for 18 h at room temperature. No fluorographic agents are used.
Cell Lines and Cycloheximide Treatment
BRCA1 mutant cell lines GM13713 (Glu1250ter), GM13705(1251del4bp), GM13709 (2135delA), GM13712(2279insA), and GM13707(390del140bp), were purchased from the Coriell Institute (Camden, New Jersey, USA). 2 ϫ 10 6 1611delC EBV transformed cells were grown in RPMI + 10% FCS with or without cycloheximide (Sigma, Saint Louis, MO, USA) at 300 µg/ml for 12 h before harvesting total RNA.
gDNA and cDNA Sequencing
Cycle sequencing was done on PCR products using Thermosequenase (Amersham, Bucks, UK). The extension products were analysed on a Licor automated sequencer (Lincoln, Ne., USA). gDNA from the 1611delC mutant was amplified by 35 cycles of amplification using primers from positions 1461-1480 and 1864-1883 of BRCA1. cDNA was used as template for nested PCR in which the 5' external primer was in exon 1 (the 5' external primer for segment 1, see Table 1 ). The internal primers were the same as those used to amplify gDNA.
Results
The entire 15 849 basepairs of coding sequence for BRCA1/2 were divided into 9 overlapping segments ranging in size from 473 to 1148 codons and having overlaps of 250 codons ( Figure 1a ). Nested PCR using cDNA as template was used to amplify segments 1, 3, 4, 5, 8, and 9, while standard PCR was used to amplify segments 2, 6, and 7 from genomic DNA (Figure 1b) . The sequences of the primers used for PCR are listed in Table 1 . PCR products were transcribed and translated into radio-labelled protein using an inexpensive homemade lysate-RNA polymerase mixture and analysed by SDS-PAGE (Figure 1c , and methods).
Sufficient Resolution With Gradient Gels
All 1143 codons of BRCA1 exon 11 are contained in segment 2. In order to determine the limits of mutation detection using tris/glycine SDS-PAGE, known truncations spanning exon 11 were analysed on a 5-18% gradient gel (Figure 2a, lanes 1-11) . The smallest difference detected between the full length protein and a mutant is seen with the 1031 residue product of the 3875del4 mutation, 16 lane 1. The 10% difference in size of these relatively large proteins is easily resolved in the upper range of the gradient gel. Lane 2 contains a 1019 residue mutant protein that is indistinguishable from that of lane 1, since they differ in size by only 1.2%. Importantly, however, the difference between the The numbers in parentheses for primers for segments 1-3 refer to the positions according to Genbank accession number U14680, except for the segment 3 external 3¢ primer, which is the reverse primer for BRCA1 exon 24 from Friedman et al 1995. For segments 4-9, the numbers refer to positions according to Genbank accession number U43746. T7 refers to the T7 polymerase and Kozak consensus sequence TAATACGACTCACTATAGGGAGACCACCATG.
A complete PTT for BRCA1 and BRCA2 A Garvin 228 mutant and wild-type signals in lane 2 is sufficient to detect the mutation. This holds true for truncations spanning exon 11 and generating products as small as 138 amino acids (lanes 3-11). An exon 11 mutant of 123 residues can be detected as well (see lane 4, Figure 2c ), although this band was not seen on some occasions, suggesting that reproducibility becomes a problem with such small fragments (see Discussion). Segment 2 has a A complete PTT for BRCA1 and BRCA2 A Garvin 230 truncation products. A mutation induced truncation product co-migrating with the doublet is easily seen in lane 7 of Figure 2a .
PTT is generally more difficult and less reliable when cDNA is used as template, and yet 48% of the coding sequence analysed by PTT in the present scheme is derived from cDNA. Figure 2b demonstrates that mutations at either end of segment 3, which contains exons 12-24 of BRCA1 amplified from cDNA, can be reproducibly detected. Lanes 1 and 2 show the segment 3 pattern for a nonsense mutation at codon 1250 in BRCA1. 16 PCR products from two independent PCR amplifications were used as template for each PTT. The expected truncation product of 137 residues is consistently detected, as well as additional unreproducible truncation products. Similarly, lanes 3 and 4 demonstrate the clear and reproducible signal from the 5438insC mutant.TEXTREF ID = "rf16" > 16 The 714 residue truncated protein is only 35 residues shorter than the wild-type protein, and yet this 5% size difference is easily resolved.
When the overlap between PTT segments is sufficient, some mutations occurring in the overlap will be detected in both segments. Figure 2c demonstrates that this is the case for BRCA1 1129insA, which generates a truncated segment 1 of 344 residues (72% of full length) and a 123 residue segment 2.
Mutations in cDNA can be Distinguished from Artefacts
PTT can often generate unreproducible truncation products when cDNA is used as template for the PCR amplification. Sequencing of the PCR product often reveals an unusual splice variant or a deletion, thus explaining the PTT result. However, confirmatory sequencing of genomic DNA fails to detect the expected splice site alteration or the expected deletion, indicating that PCR products derived from cDNA template are prone to artefacts. The over-representation of an unusual splice variant can be explained by fortuitous PCR amplification of that particular species, whilst a deletion can be explained by internal priming by partially extended PCR products, and subsequent preferential amplification of the smaller amplicon. In any case, these are PCR artefacts that occur randomly during the amplification process and should not be reproducible. Figure 3 demonstrates this to be the case for segment 8 of patient 4. The cDNA from patient 4 was of low quality and was difficult to amplify, however PCR products of the correct size were eventually generated. Unlike the control pattern, the PTT pattern for patient 4 was inconsistent. For comparison, patient 25 has a reproducible truncation product of 373 residues due to a two base-pair deletion at position 7297 in exon 14 of BRCA2. For each cDNA template, independent PCR amplifications were performed, and each PCR product was used as template for PTT.
Nonsense-mediated mRNA Decay is Inhibited by Cycloheximide
Premature termination of protein synthesis in eukaryotes can result in message instability, a process termed nonsense-mediated mRNA decay (recently reviewed by Jacobson and Pelzt. 17 Importantly, transcript instability for a number of BRCA1 mutants has been reported. 18, 19 Although truncating BRCA1 and BRCA2 mutations can be identified using cDNA as starting material (see Figures 2b, 2c and 3) , nonsense mediated decay in a subset of BRCA1/2 mutants will increase the false negative rate for any test that uses cDNA as starting material and is a cause for concern. The mechanism responsible for mRNA instability in certain BRCA1 mutants is unclear; however, it is reasonable to propose that protein synthesis is required for the cell to discriminate between mutant and wild-type messages. In such a scenario, global inhibition of protein synthesis should equalise the steady state levels of mutant and wild-type mRNA. Figure 4 demonstrates this is the case A complete PTT for BRCA1 and BRCA2 A Garvin 231 for the previously characterised BRCA1 1611delC mutant. 14 EBV transformed cells harbouring the mutation were grown in the presence or absence of cycloheximide, an inhibitor of protein synthesis. Genomic DNA or cDNA was used as template to amplify codons 447-581 of BRCA1 and the PCR products were sequenced. Genomic DNA has the expected diminished signal for the T residue at 1612 and an equivalent T signal at 1611 due to the 1 base-pair deletion in the mutant allele. Mutant cDNA from untreated cells gives a barely detectable T signal at position 1611, while the cDNA from cycloheximide treated cells generates a signal intensity equal to that obtained with mutant genomic DNA, indicating that nonsense-mediated mRNA decay has been inhibited. Similar inhibition of nonsense mediated decay was obtained when protein synthesis was inhibited in a cell line containing the gln526ter mutation (data not shown).
Discussion
Mutation detection in the BRCA1 and BRCA2 genes poses a formidable challenge. Many unidentified BRCA1/2 mutations still exist in the human population, implying that the rapid and simple methods which detect known mutations will have an unacceptably high false negative rate. Furthermore, mutations are spread throughout the genes, thus a complete scan of the 5283 codons contained in BRCA1/2 is required for an accurate screen. DNA sequencing is one method for detecting mutations in BRCA1/2 and involves generating, collecting, and analysing 32 000 data points, since both strands of the 16 kb of coding sequence must be sequenced. This approach can detect the presence of mutations, but it will also provide an enormous amount of unneeded information, namely the complete BRCA1/2 gene sequence of the patient. The cost of this unnecessary information is reflected in the cost of the assay, which is often prohibitive. Fortunately, other methods are available which provide less information than sequencing, but are effective in detecting mutations.
PTT provides very limited information on the test sequence in that it only detects mutations resulting in premature termination of protein synthesis. The limited information content of PTT is reflected in its rapidity and low cost. A theoretical PTT of BRCA1 and BRCA2 relying on nine overlapping segments will generate nine wild-type data points representing the full length protein products, and the presence or absence of one (or at most two) additional data points indicating the presence of a mutation.
Limitations of SDS-PAGE
All examples of PTT published to date use tris/glycine SDS-PAGE to determine protein size. It is important when using this technique to keep in mind that the relation of logMW to relative mobility is linear over only a limited range of molecular weight. On a 12% gel, for example, proteins with a molecular mass below 16 000 run with the buffer front, and thus with unincorporated radio-labelled methionine, 20 and higher acrylamide concentrations do little to improve the 
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A Garvin 232 lower limit of detection. The resolution of small proteins can be improved by using tricine/urea gels, although some proteins are still not detected because they are eluted from the gel during the washing step. 21 Since a washing step to remove unincorporated S-35 methionine is required when doing PTT, and since tricine is relatively expensive and not commonly used for SDS-PAGE, 130 residues can be considered a conservative lower limit of detection for PTT when 5-18% gradient gels are used with a tris/glycine buffer. The largest segments used for screening BRCA1/2 are the 1143 and 1148 residue segments 2 and 7, respectively. As shown in Figure 2a , a 10% reduction (115 residues) in size for these large segments is enough to detect a mutation. Therefore, the overlap between segments should be at least 245 (130 + 115) residues to insure proper coverage at the segment junctions. Overlaps of this size are much larger than the 14-22 codon overlaps used in DMD screening, 22 and the 9-107 codon overlaps used for the first BRCA1 PTT. 12 In the present study all overlaps are 250 residues, leaving only the 5' and 3' ends of BRCA1/2 without adequate coverage. The 5' ends of each gene lack coverage for the first 130 codons. Mutations truncating segments 3 and 9 by less than 10% (75 and 83 residues, respectively) at the 3' end of each gene might also be scored as false negatives, although this is a conservative figure, since a 5% shift in segment 3 was detected in lanes 3 and 4 of Figure 2b . Thus truncations occurring within a total of 418 codons, or 8% of the BRCA1/2 coding sequence, might be missed due to the limitations of tris/glycine SDS-PAGE. Assuming that truncating mutations are spread evenly throughout the BRCA1/2 coding sequence, 92% of the truncated proteins generated in the coupled transcription/translation reaction can be detected. Since 90% of BRCA1/2 mutations result in truncations, the theoretical false negative rate for this PTT screen is 17%, assuming that the problem of nonsense mediated mRNA decay is adequately resolved.
PCR Artefacts when Using cDNA Template
The low abundance of BRCA1 and BRCA2 mRNA in peripheral blood leukocytes necessitates nested PCR amplification of cDNA. Under the PCR conditions used, a significant and apparently unavoidable number of PCR amplifications from cDNA template generates artefacts that produce truncated protein products in the PTT. Much time and effort can be wasted attempting to find the alterations in gDNA responsible for these false positive signals. Fortunately these artefacts are distinguished from true mutations by their irreproducibility. Thus any putative mutation detected by PTT when cDNA is the starting material should first be verified by an independent nested PCR-PTT before proceeding with sequencing.
Nonsense Mediated mRNA Decay
cDNA is used as starting material for 48% of the BRCA1/2 PTT screen. In such an approach mutant message must be present at detectable levels in the patient's cells that serve as a source of mRNA. For at least six BRCA1 mutations this is not the case and premature truncation of the BRCA1 protein is accompanied by loss of transcript. 18, 19 Clearly then, nonsense mediated decay of BRCA1/2 mRNA can increase the false negative rate of a PTT screen.
The 1611de1C mutation in BRCA1 results in loss of transcript 18, 19 (see Figure 4) , and yet many other truncating mutations both 5' and 3' to 1611 do not. The 185de1AG mutation of BRCA1, for example, can be easily detected by sequencing cDNA (data not shown), indicating that truncating mutations at the extreme 5' end of the coding sequence do not necessarily lead to loss of transcript. Similarly the nonsense mutation at codon 1828 at the extreme 3' end of BRCA1 is easily detectable from cDNA (see Figure 2b, lanes 3 and 4) . In yeast, cis-acting sequences 3' to the premature stop codons are required for mRNA destabilisation. 23 Perhaps similar elements are adjacent to the BRCA1 mutations which cause nonsense mediated mRNA decay, but are not adjacent to those mutations that have no effect on message stability.
Regardless of the mechanism of nonsense mediated mRNA decay, any means to stabilise mutant message should increase the accuracy of PTT and any other mutation detection scheme that relies on cDNA. Thus the finding that inhibition of protein synthesis by cycloheximide treatment can stabilise mutant BRCA1 mRNA may have practical applications. Perhaps routine cycloheximide treatment of blood samples prior to RNA isolation will reduce that component of the false negative rate caused by nonsense mediated mRNA decay.
